Jie YS - Search Results

1

Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.

Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J. Liu X, et al. Among authors: jie ys. Lancet. 2024 Jun 22;403(10445):2720-2731. doi: 10.1016/S0140-6736(24)00594-4. Epub 2024 May 30. Lancet. 2024. PMID: 38824941 Clinical Trial.

2

A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.

Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. Lin XJ, et al. Lancet Oncol. 2015 Jul;16(7):804-15. doi: 10.1016/S1470-2045(15)00048-0. Epub 2015 Jun 15. Lancet Oncol. 2015. PMID: 26088272

3

The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy.

Zeng Y, Huang J, Pang J, Pan S, Wu Y, Jie Y, Li X, Chong Y. Zeng Y, et al. Front Immunol. 2024 Mar 15;15:1330644. doi: 10.3389/fimmu.2024.1330644. eCollection 2024. Front Immunol. 2024. PMID: 38558804 Free PMC article.

4

A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China.

Lei Z, Cao H, Jie Y, Huang Z, Guo X, Chen J, Peng L, Cao H, Dai X, Liu J, Li X, Zhu J, Xu W, Chen D, Gao Z, He JR, Lin BL. Lei Z, et al. Travel Med Infect Dis. 2020 May-Jun;35:101664. doi: 10.1016/j.tmaid.2020.101664. Epub 2020 Apr 9. Travel Med Infect Dis. 2020. PMID: 32278758 Free PMC article.

5

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA.

Shi H, Huang M, Lin G, Li X, Wu Y, Jie Y, Chong Y. Shi H, et al. Biomed Res Int. 2016;2016:6725073. doi: 10.1155/2016/6725073. Epub 2016 Mar 1. Biomed Res Int. 2016. PMID: 27034945 Free PMC article.

6

Efficacy of long-term treatment with tenofovir in Chinese nucleos(t)ide-naïve chronic hepatitis B patients regardless of baseline viral load.

Luo J, You X, Chong Y, Wu Y, Gong J, Jie Y, Li X, Xi S, Zhang Z, Zhang Y, Xie D, Li Z, Li X. Luo J, et al. Exp Ther Med. 2019 Jul;18(1):260-268. doi: 10.3892/etm.2019.7547. Epub 2019 May 6. Exp Ther Med. 2019. PMID: 31258661 Free PMC article.

7

Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure.

Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Shi H, et al. Biomed Pharmacother. 2021 Feb;134:111118. doi: 10.1016/j.biopha.2020.111118. Epub 2020 Dec 16. Biomed Pharmacother. 2021. PMID: 33341047 Free article.

8

An early novel prognostic model for predicting 80-day survival of patients with COVID-19.

Chen Y, Gong J, He G, Jie Y, Chen J, Wu Y, Hu S, Xu J, Hu B. Chen Y, et al. Front Cell Infect Microbiol. 2022 Oct 27;12:1010683. doi: 10.3389/fcimb.2022.1010683. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36389149 Free PMC article. Clinical Trial.

9

U-Shaped Relationship of Low-Density Lipoprotein Cholesterol With Risk of Severe COVID-19 From a Multicenter Pooled Analysis.

Gong J, Chen Y, Jie Y, Tan M, Jiang Z, Yuan L, Cao J, Li G, Chong Y, Qu J, Shi Y, Hu B. Gong J, et al. Front Cardiovasc Med. 2021 Aug 24;8:604736. doi: 10.3389/fcvm.2021.604736. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34504873 Free PMC article.

10

Assessing the impact of comorbid type 2 diabetes mellitus on the disease burden of chronic hepatitis B virus infection and its complications in China from 2006 to 2030: a modeling study.

Xie J, Wang X, Wang X, Li J, Jie Y, Hao Y, Gu J. Xie J, et al. Glob Health Res Policy. 2024 Jan 22;9(1):5. doi: 10.1186/s41256-024-00345-2. Glob Health Res Policy. 2024. PMID: 38246986 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters